PEGDOXINE Doxorubicin Hydrochloride pegylated liposomal Injection 20mg /10ml

About PEGDOXINE Doxorubicin Hydrochloride pegylated liposomal Injection 20mg /10ml

Doxorubicin Hydrochloride Pegylated Liposomal Injection is a liposomal formulation of doxorubicin, a chemotherapy drug. Doxorubicin is an anthracycline antibiotic that works by interfering with the DNA of cancer cells, preventing them from dividing and growing. The "pegylated liposomal" part refers to the drug being encapsulated in tiny fat-like particles (liposomes) and modified with a polymer called polyethylene glycol (PEG). This formulation helps improve the delivery of the drug to cancer cells while reducing some of the side effects typically associated with traditional doxorubicin.

Key characteristics of pegylated liposomal doxorubicin:

• Enhanced delivery: The liposomal formulation allows for better targeting of the drug to cancer cells, potentially increasing its effectiveness while reducing harm to healthy cells.
• Reduced side effects: The pegylation and liposomal encapsulation reduce the risk of severe side effects like heart toxicity and hair loss, which are more common with traditional doxorubicin.

Common uses of Pegylated Liposomal Doxorubicin:

1. Ovarian cancer: Often used for advanced or recurrent ovarian cancer.
2. Breast cancer: Used for metastatic or advanced breast cancer, especially after other treatments have been tried.
3. Kaposi's sarcoma: Particularly in patients with HIV/AIDS.
4. Other cancers: It may also be used in the treatment of certain other cancers depending on the individual patient's situation and response to treatment.

How it works:

Doxorubicin, the active ingredient in this injection, interferes with the cancer cell's ability to replicate its DNA, leading to cell death. The liposomal encapsulation allows the drug to stay in circulation longer and accumulate in tumors more effectively, minimizing damage to normal tissues.

Common side effects of pegylated liposomal doxorubicin:

• Nausea and vomiting
• Fatigue
• Hand-foot syndrome (redness, swelling, and pain on the hands and feet)
• Low blood counts (which can increase the risk of infection, anemia, or bleeding)
• Mouth sores
• Hair thinning or hair loss
• Heart problems: Though the liposomal formulation reduces the risk, it can still cause heart-related side effects, such as heart failure in some patients.
• Liver toxicity: This medication can affect liver function, so liver enzyme tests are typically monitored during treatment.

Important considerations:

• Heart function monitoring: Since doxorubicin can affect heart health, your doctor may perform regular heart function tests (e.g., echocardiograms) to ensure the drug isnt causing any damage.
• Blood tests: Frequent blood tests will be needed to monitor for low blood cell counts and liver function.
• Infusion reactions: Some patients may experience reactions during the infusion, such as fever, chills, or skin reactions, which should be reported to your healthcare team.
• Pregnancy and breastfeeding: This drug is contraindicated during pregnancy as it can harm the fetus, and it's not recommended for breastfeeding.

Administration:

This medication is typically given as an intravenous (IV) infusion by a healthcare professional in a clinical setting. The dosage and frequency will depend on the type of cancer, the patient's health, and their response to previous treatments.

If you're receiving or considering pegylated liposomal doxorubicin for treatment, make sure to discuss any concerns, side effects, or pre-existing conditions with your healthcare provider to ensure proper management of the treatment plan.

Advanced PEGylated Liposomal Delivery

PEGDOXINE leverages PEGylated liposomal technology, allowing for prolonged circulation of doxorubicin in the bloodstream. This innovation not only improves tumor cell targeting but also reduces exposure to healthy tissues, minimizing adverse effects and enhancing therapeutic outcomes in cancer patients.


Comprehensive Cancer Indications

This cytotoxic chemotherapeutic agent is indicated for multiple serious malignancies, including ovarian cancer, multiple myeloma, Kaposi's sarcoma, and breast cancer. Its versatility makes PEGDOXINE an essential treatment option within hospitals, clinics, and cancer hospice settings.


Quality & Safety Assured

Manufactured in a WHO-GMP certified facility, PEGDOXINE undergoes rigorous quality and safety checks. Each sterile vial is intended for single use and should be stored between 2C and 8C, protected from light, to maintain pharmaceutical integrity and efficacy.